Bio-Safety Level 3 Core

The Ragon BSL3 core provides biosafety level-3 laboratory space, training, and consultation for academic and industrial researchers working with risk group-3 pathogens, such as M. tuberculosis, SARS-CoV-2, Chikungunya virus, West Nile virus, Powassan virus, Japanese Encephalitis virus, Dabie bandavirus, Heartland virus and Bhanja virus. 

Researchers are required to complete 30 hours of BSL3 specific training to become certified BSL3 core users. Training covers special facility containment, BSL-3 specific PPE, and safety regulations specific to risk group-3 pathogens.

Director

Amy Barczak

Scientific Director

Contact

Julie Boucau

Co-Director

Yong (Mike) Xie

Director

Services and Pricing

The Ragon BSL3 is one of the largest (2200 square feet) and most heavily used BSL3 facility in the region, with an excellent safety track record. The lab is equipped with dedicated 12-color high-speed cell sorter and microscopy equipment, as well as cell culture hoods and standard cell and molecular biology resources.

Learn More

Selected Publications

Virologic Features of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children

Yonker LM, Boucau J, Regan J, Choudhary MC, Burns MD, Young N, Farkas EJ, Davis JP, Moschovis PP, Bernard Kinane T, Fasano A, Neilan AM, Li JZ, Barczak AK

J Infect Dis . 2021 Dec 1;224(11) PubMed

Duration of viral shedding and culture positivity with postvaccination SARS-CoV-2 delta variant infections

Siedner MJ, Boucau J, Gilbert RF, Uddin R, Luu J, Haneuse S, Vyas T, Reynolds Z, Iyer S, Chamberlin GC, Goldstein RH, North CM, Sacks CA, Regan J, Flynn JP, Choudhary MC, Vyas JM, Barczak AK, Lemieux JE, Li JZ

JCI Insight . 2022 Jan 25;7(2):e155483 PubMed

Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection

Boucau J, Chew KW, Choudhary M, Deo R, Regan J, Flynn JP, Crain CR, Hughes MD, Ritz J, Moser C, Dragavon JA, Javan AC, Nirula A, Klekotka P, Greninger AL, Coombs RW, Fischer WA, Daar ES, Wohl DA, Eron JJ, Currier JS, Smith DM, Li JZ, Barczak AK; ACTIV-2/A5401 Study Team.

medRxiv . 2021 Dec 30;2021.12.25.21268211. doi: 10.1101/2021.12.25.21268211 PubMed

SARS-CoV-2 Persistence and Evolution in an Immunocompromised Host

Choi B, Choudary M, Regan J, Sparks JA, Padera RF Jr, Qiu X, Solomon I, Kuo HH, Boucau J, Bowman KA, Das Adhikari U, Winkler ML, Mueller AM, Hsu TY, Desjardins M, Baden L, Chan B, Walker BD, Lichterfeld MD, Brigl M, Kwon DK, Kanjilal S, Richardson ET, Jonsson AH, Alter G, Barczak AK, Hanage WP, Yu XG, Gaiha G, Seaman M, Cernadas M, Li J

New England Journal of Medicine 2020 Dec 3; 383(23) PubMed

Determining the Incidence of Asymptomatic SARS-CoV-2 among Early Recipients of COVID-19 Vaccines: A Prospective Cohort Study of Healthcare Workers before, during and after Vaccination [DISCOVER-COVID-19]

North CM, Barczak AK, Goldstein RH, Healy B, Finkelstein DM, Ding D, Kim J, Boucau J, Shaw B, Gilbert B, Vyas T, Reynolds Z, Regan J, Flynn J, Choudary M, Vyas J, Laskowski K, Dighe A, Lemieux J, Li JZ, Baden LR, Siedner MJ, Woolley AE, Sacks CA

Clinical Infectious Disease 2021 Aug 7 PubMed